Genmab (GMAB) reported Q1 earnings Thursday of $3.05 per diluted share, up from $2.94 a year earlier.
Revenue for the quarter ended March 31 was $715 million, compared with $603 million a year earlier.
Analysts polled by FactSet expected $735.9 million.
Genmab reiterated its 2025 financial guidance from Feb. 12.
Shares of Genmab were down more than 4% in recent trading.
Price: 19.62, Change: -0.99, Percent Change: -4.78